TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03037424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octafibrin
Description: Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
Study: NCT03803254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT03097211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
Study: NCT04376164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
Study: NCT00512408

Intervention type: DRUG
Intervention: testosterone
Study: NCT04356066

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum cxcl10 by ELISA
Description: serum sample
Study: NCT03286725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Education (PE) Programme
Description: A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons.
Study: NCT03803254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study: NCT02995564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social skills therapy
Description: Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
Study: NCT02655224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix placebo-matching tablets
Study: NCT01867190

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ASCT01 (Autologous Stem Cell Transplantation)
Description: Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
Study: NCT05344079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump
Description: spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study: NCT00265785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
Study: NCT02695927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer rehabilitation glasses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer rehabilitation glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer rehabilitation glasses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer rehabilitation glasses
Study: NCT05072119

Intervention type: DEVICE
Intervention: Device implantation
Description: Implantation of single chamber, dual chambers or triple chambers PM/ICD

Intervention type: DEVICE
Intervention: Device implantation
Description: Implantation of single chamber, dual chambers or triple chambers PM/ICD

Intervention type: DEVICE
Intervention: Device implantation
Description: Implantation of single chamber, dual chambers or triple chambers PM/ICD
Study: NCT02241798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: O2 by nasal prongs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: O2 by nasal prongs
Study: NCT01487629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, 1.5 mg, intravitreal, throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab, 0.5 mg, intravitreal, throughout the study
Study: NCT02562287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Flexible dosage, with up-titration according to standard schedules employed for schezophrenia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone, in a flexible dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, flexible dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine, flexible dosage
Study: NCT02998606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: MOVANTIK™ 25 mg, daily
Study: NCT01681641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A psycho-social intervention
Study: NCT03268278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine plus local anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Placebo 1,8 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, epinephrine (Local anesthetic)
Description: 2% lidocaine 1:100,000 epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine, epinephrine (Local anesthetic)
Description: 2% lidocaine 1:100,000 epinephrine
Study: NCT03462121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201
Description: RPh201 is a well-defined extract from a botanical source

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo consisting of the therapeutic vehicle
Study: NCT02117076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin immediate release
Description: up to 1200 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin enacarbil extended release
Description: up to 1200 mg per day
Study: NCT04070846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] LC350189
Description: Carbon-14 labelded LC350189
Study: NCT02411851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ingenol mebutate 0.015%
Description: one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 0.015%
Description: one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermasil lotion
Description: Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
Study: NCT03683082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen supplementation
Description: 40% FiO2 via Venturi mask

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham O2 (medical air)
Description: Medical air supplementation via Venturi mask
Study: NCT01516476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6807952
Description: multiple doses for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6807952
Description: multiple doses for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: liraglutide for 12 weeks
Study: NCT04528186

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal thyroid volume
Description: Maternal thyroid volume measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal thyroid volume
Description: Maternal thyroid volume measurement
Study: NCT03043573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH-MCI
Description: Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
Study: NCT03757949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive SIM PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04175184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with Movement
Description: MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Mobilisation with Movement
Description: Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
Study: NCT04469686

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
Description: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
Description: Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Twice daily placebo suppository administered with Sephure applicator
Description: Twice daily placebo suppository administered with Sephure applicator
Study: NCT01675440

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Study: NCT02998606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo 25 mg, daily
Study: NCT04470310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Specified dose on specified days
Study: NCT01191606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the change of ventilatory mode
Description: One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
Study: NCT04470310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin 25Mg Tab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet
Study: NCT03755336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administered Slip Perturbations
Description: Slips will be administered in early, middle or late phases of stance during overground walking.
Study: NCT03263533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Oral Capsule Group 1
Description: Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Oral Capsule Group 2
Description: Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
Study: NCT03242031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monospot panretinal photocoagulation
Description: panretinal photocoagulation with monospot laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multispot panretinal photocoagulation
Description: panretinal photocoagulation with multispot laser
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Specified dose on specified days
Study: NCT01191606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the change of ventilatory mode
Description: One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
Study: NCT01203917

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: 250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
Study: NCT04511572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embolization of the middle meningeal artery
Description: The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
Study: NCT00917735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green tea extract supplement
Description: Two green tea extract capsules twice daily after breakfast and dinner for one year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules twice daily after breakfast and dinner for one year
Study: NCT04139863

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: aMMP-8 chairside test
Description: No test
Study: NCT01764750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrasite Vancomycin
Description: Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrasite Vancomycin
Description: Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrasite Vancomycin
Description: Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin
Description: IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.